Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $11

Benzinga · 2d ago
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $9 to $11.